Academic Journal
A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan.
| Τίτλος: | A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. |
|---|---|
| Συγγραφείς: | Chiu CF; Division of Pediatric Endocrinology and Genetics, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan; School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: chioufan@cgmh.org.tw., Chou CK; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan; Obesity Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan. Electronic address: 07312@cych.org.tw., Hu SW; Chia An Medical Clinic, Taichung, Taiwan; Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan; Doctoral Program in Translational Medicine, Department of Life Sciences, National Chung Hsin University, Taichung, Taiwan. Electronic address: d111080004@mail.nchu.edu.tw., Huang KC; Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: bretthuang@ntu.edu.tw., Wu YL; Department of Pediatric Endocrinology, Changhua Christian Children's Hospital, Changhua, Taiwan. Electronic address: 162991@cch.org.tw., Wu HF; Department of Pediatrics, Kuang Tien General Hospital, Taichung, Taiwan; Weight Management Center, Kuang Tien General Hospital, Taichung, Taiwan. Electronic address: 3178@ktgh.com.tw., Liu YL; Medical Affairs, Novo Nordisk Taiwan. Electronic address: ejay.liu@boehringer-ingelheim.com., Yang YC; Medical Affairs, Novo Nordisk Taiwan. Electronic address: YCYG@novonordisk.com., Chen HL; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University Children's Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University Children's Hospital, Taipei, Taiwan; Department and Graduate Institute of Medical Education and Bioethics, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: hueyling@ntu.edu.tw., Yeung CY; Department of Pediatrics, Hsinchu Municipal MacKay Children's Hospital, Hsinchu, Taiwan; Department of Medicine, MacKay Medical University, New Taipei City, Taiwan. Electronic address: cyyeung@mmh.org.tw. |
| Πηγή: | Obesity research & clinical practice [Obes Res Clin Pract] 2026 Sep-Oct; Vol. 20 (5), pp. 437-444. Date of Electronic Publication: 2026 Sep 15. |
| Τύπος έκδοσης: | Journal Article; Multicenter Study; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101303911 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1871-403X (Print) Linking ISSN: 1871403X NLM ISO Abbreviation: Obes Res Clin Pract Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam : Elsevier, 2007- |
| Ιατρικοί όροι (MeSH): | Hypoglycemic Agents*/therapeutic use , Liraglutide*/therapeutic use , Pediatric Obesity*/drug therapy , Glucagon-Like Peptide-1 Receptor Agonists*, Weight Loss/drug effects ; Adolescent ; Child ; Female ; Humans ; Male ; Body Mass Index ; Prospective Studies ; Taiwan ; Treatment Outcome |
| Περίληψη: | Background and Aims: Pediatric obesity is linked to many metabolic complications and has limited treatment options. We evaluated the safety and effectiveness of GLP-1 receptor agonist (liraglutide) in adolescents with obesity in clinical practice in Taiwan. Methods: We conducted a prospective study (NCT06283641) across 14 hospitals and clinics from February 2024 to March 2025 evaluating adolescents receiving liraglutide at baseline, week 13, and week 26. Demographics, and safety and effectiveness outcomes, including incidence proportions of adverse events and adverse drug reactions, and changes in body weight and body mass index, were assessed. Results: Among 41 participants, 22 (53.7%) were male, with mean age (±standard deviation) 13.9 ± 1.8 years, body weight (BW) 88.5 ± 19.3 kg, and body mass index (BMI) 33.4 ± 5.1 kg/m2. Nineteen (46.3%) had medical history of hepatic impairment. Mean daily and maximum doses were 1.4 ± 0.5 mg/day and 1.8 ± 0.7 mg/day, respectively, throughout 128.3 ± 56.0 days; 14.4% escalated to 3.0 mg/day. Overall respective incidence proportions of adverse events and adverse drug reactions were 19.5% (8/41; all mild) and 9.8% (4/41; 6 events), respectively. Gastrointestinal events were most frequent, followed by injection site-related events. No treatment discontinuation resulted from intolerance. Mean respective losses in BW, BMI, and BMI standard deviation score at weeks 13 and 26 were -2.7 ± 3.8 kg (p = 0.0003), -1.3 ± 1.4 kg/m2 (p < 0.0001), and -0.2 ± 0.2 (p < 0.0001); and -4.4 ± 5.7 kg (p = 0.0015), -1.9 ± 2.1 kg/m2 (p = 0.0004), and -0.4 ± 0.3 (p < 0.0001), respectively. Conclusion: In adolescents with obesity in Taiwan, liraglutide at doses below 3.0 mg/day was well-tolerated, and reductions in BW, BMI, and BMI standard deviation score were observed. (Copyright © 2026 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| Competing Interests: | Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Chiao-Fan Chiu reports financial support, article publishing charges, statistical analysis, and writing assistance were provided by Chang Gung Memorial Hospital, Taoyuan, Taiwan. Shu-Wei Hu reports article publishing charges, statistical analysis, and writing assistance were provided by Novo Nordisk Pharma Taiwan, Ltd. Hsiang-Fan Wu reports financial support was provided by Department of Pediatrics, Kuang Tien General Hospital, Taichung, Taiwan. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Adolescents; GLP-1 RA; Liraglutide; Obesity; Real-world evidence; Taiwan |
| Substance Nomenclature: | 0 (Glucagon-Like Peptide-1 Receptor Agonists) 0 (Hypoglycemic Agents) 839I73S42A (Liraglutide) |
| Entry Date(s): | Date Created: 20260915 Date Completed: 20261007 Latest Revision: 20261009 |
| Update Code: | 20261010 |
| DOI: | 10.1016/j.orcp.2026.09.001 |
| PMID: | 42744726 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!